TERT p Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real‐World Study
Cancer Medicine · 2025
DOI: 10.1002/cam4.70533 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Hao Xing und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy o…. Hauptthemen laut MEDLINE: Glioma, Mutation, Telomerase, Brain Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Beijing Municipal Natural Science Foundation, the National High Level Hospital Clinical Research Funding, the Tsinghua University-Peking Union Medical College Hospital Initiative Scientific Research Program.
Abstract (Originalsprache)
Background
The 2021 WHO Classification of Central Nervous System Tumors introduces more molecular markers for glioma reclassification, including TERT promoter ( TERT p) mutation as a key feature in glioblastoma diagnosis.
Aims
Given the changes in the entities included in each subtype under the new classification, this research investigated the distribution, prognostic value, and correlations with other molecular alterations of TERT p mutation in different subgroups under this latest classification.
Methods
All glioma patients admitted to Peking Union Medical College Hospital for surgical resection or biopsy from 2011 to 2022 were included. Samples were analyzed for TERT p mutation and 59 other gene alterations and chromosome copy number variations.
Results
A total of 207 patients were included. The occurrence of TERT p mutations varied with percentages of 4.55%, 100%, and 77.92% in astrocytoma, oligodendroglioma, and glioblastoma, respectively. 65% of all adult‐type glioma patients and 42.6% of IDH‐wildtype histology grade 2 or 3 patients were TERT p‐mutant. Survival analysis showed that TERT p mutation was a predictor of better prognosis in IDH‐mutant grade 2 gliomas (median OS (mOS): not reached (NA) (95% CI: NA–NA) vs. 75.9 (95% CI: 55.4–NA) months, HR = 0.077 (95% CI: 0.01–0.64), p = 0.003), while poor OS was associated with all Grade 4 gliomas (mOS: 17.5 (95% CI: 12.6–24.2) vs. 40.5 (95% CI: 24.4–83.8) months, HR = 2.014 (95% CI: 1.17–3.47), p = 0.01) and all IDH‐wildtype histology grade 2 or 3 gliomas (median OS: 12.6 (95% CI: 11–24.2) vs. 83.8 (95% CI: 35.2–NA) months, HR = 3.768 (95% CI: 1.83–7.78), p < 0.001). Moreover, TERT p mutation tended to co‐occur with EGFR, KRAS, and MET in glioblastoma. In the IDH‐mutant subgroup, it tended to co‐occur with CIC and FUBP1 alterations, while being mutually exclusive with ATRX and TP53 alterations. These correlations may further refine prognostic predictions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- China Anti-Cancer Association Specialty Committee of Glioma, Beijing, China.
- Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID-Profile: Yaning Wang, Siying Guo, Yu Wang, Wenbin Ma
Förderung
- the Beijing Municipal Natural Science Foundation
- the National High Level Hospital Clinical Research Funding
- the Tsinghua University-Peking Union Medical College Hospital Initiative Scientific Research Program
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Xing, H., Liu, D., Li, J., Ge, Y., Guo, X., Chen, W., Zhao, D., Shi, Y., Li, Y., Wang, Y., Wang, Y., Xia, Y., Wu, J., Liang, T., Wang, H., Liu, Q., Jin, S., Qu, T., Guo, S., …, & Ma, W. (2025). TERT p Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real‐World Study. Cancer Medicine. https://doi.org/10.1002/cam4.70533
Vancouver
Xing H, Liu D, Li J, Ge Y, Guo X, Chen W, et al. TERT p Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real‐World Study. Cancer Medicine. 2025. doi:10.1002/cam4.70533
BibTeX
@article{Xing2025,
author = {Xing, Hao and Liu, Delin and Li, Junlin and Ge, Yulu and Guo, Xiaopeng and Chen, Wenlin and Zhao, Dachun and Shi, Yixin and Li, Yilin and Wang, Yaning and Wang, Yuekun and Xia, Yu and Wu, Jiaming and Liang, Tingyu and Wang, Hai and Liu, Qianshu and Jin, Shanmu and Qu, Tian and Guo, Siying and Li, Huanzhang and Yang, Tianrui and Zhang, Kun and Wang, Yu and Ma, Wenbin},
title = {TERT p Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real‐World Study},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70533}
}
EUVIMED